Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients

PURPOSE: We used targeted capture sequencing to analyze TP53‐mutated circulating tumor DNA (ctDNA) in metastatic breast cancer patients and to determine whether TP53 mutation has predictive value for anti‐human epidermal growth factor receptor 2 (HER2) treatment for in HER2 amplification‐positive pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Binliang, Yi, Zongbi, Guan, Yanfang, Ouyang, Quchang, Li, Chunxiao, Guan, Xiuwen, Lv, Dan, Li, Lixi, Zhai, Jingtong, Qian, Haili, Xu, Binghe, Ma, Fei, Zeng, Yixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302303/
https://www.ncbi.nlm.nih.gov/pubmed/35393784
http://dx.doi.org/10.1002/cam4.4652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302303/
https://www.ncbi.nlm.nih.gov/pubmed/35393784
http://dx.doi.org/10.1002/cam4.4652

Ejemplares similares